CzMA JEP: Current issue
About the journal
Editorial Board
For authors and reviewers
Contact us


Authors: Pavelková A., Pavelka K.

Authors - sphere of activity: Revmatologický ústav, Praha

Article: Čes. Revmatol., , 2000, No. 2, p. 57-61.
Number of articles displayed: 2897x

Specialization: Dermatology & STDs Paediatric rheumatology Rheumatology


The authors present the pharmacological profile and an account of the clinical effectiveness ofdiacerein. It is a preparation which inhibits above all the production and activity of interleukin-1(IL-1) as well as other cytokines and catabolic enzymes which participate in the degradation ofcartilage in osteoarthritis (OA). The implemented clinical studies provide evidence of its effective-ness on pain and function in patients with hip and knee osteoarthritis. As to the character of itseffect diacerein belongs to so-called SYSADOA, symptomatically slow acting drugs in OA. The onsetof its effect is as compared with NSA retarded, the onset being after 2-4 weeks. Then its effectivenessis identical as that of NSA. While after discontinuation of NSA treatment the patients exacerbatesas a rule, after termination of diacerein treatment the favourable effect persists for another 2-3months. A recently completed study revealed that in addition to the purely symptomatic effect afterlong-term diacerein treatment the progression of OA is perhaps slower. Thus a drug potentiallymodifying the structure is involved. The assembled results will have to be confirmed in furtherinvestigations. Diacerein is a safe preparation, the main undesirable effect is diarrhoea whichhowever occurs only at the onset of treatment and as a rule does not lead to discontinuation oftherapy.

Key words:
osteoarthritis, diacerein, therapy, SYSADOA



The full wording of this article is not available in digital format, because the printed version editor has not released it yet. Send us your request and we will gladly pass it on to the editor’s office.

Hodnocení článku

Rate article:     2,9/5, evaluated 33x

Klinické korelace antinukleárníchautoprotilátek u sklerodermie

Štork J., Vencovský J., Kafková J., Bečvář R.
Česká revmatologie

Systémový lupus erythematodes a počítačová tomografie mozku

J. Böhm, C. Dostál, J. Obenberger, V. Peterová 3
Česká revmatologie

K. Kupka, C. Dostál, V. Peterová, M. Olejárová, J. Obenberger, Z. Seidl 4
Česká revmatologie

Malé molekuly RNA a jejich význam v imunitní odpovědi organismu

Škoda M, Novota P, Remáková M, Faustová M, Vencovský J
Česká revmatologie

Výskyt infekcí při léčbě antagonisty TNF alfa v registru ATTRA

Šléglová O., Burešová L., Vencovský J., Pavelka K.
Česká revmatologie